The Role of IL5 in Epithelial Cell Integrity

Description

The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells

Conditions

Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells

The Role of IL5 in Epithelial Cell Integrity

The Role of IL5 in Epithelial Cell Integrity

Condition
Chronic Rhinosinusitis With Nasal Polyps
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States, 21117

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell.
  • * (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and
  • * (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan.
  • * 1. Children under the age of 18 will be excluded due to:
  • 1. possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population.
  • 2. lack of complete pneumatization of the majority of paranasal sinuses
  • * 2. pregnant or lactating females,
  • * 3. prisoners,
  • * 4. mentally disabled
  • * 5. persons unable to give informed consent will be contemplated for inclusion.
  • * 6. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm.
  • * 7. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery
  • * 8. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab.

Ages Eligible for Study

18 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Jean Kim, MD PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2025-06